메뉴 건너뛰기




Volumn 10, Issue 1, 2012, Pages

HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy

(21)  Fountzilas, George a   Valavanis, Christos b   Kotoula, Vassiliki a   Eleftheraki, Anastasia G c   Kalogeras, Konstantine T a,c   Tzaida, Olympia b   Batistatou, Anna d   Kronenwett, Ralf e,k   Wirtz, Ralph M e,l   Bobos, Mattheos a   Timotheadou, Eleni a   Soupos, Nikolaos f   Pentheroudakis, George d   Gogas, Helen f   Vlachodimitropoulos, Dimitrios f   Polychronidou, Genovefa a   Aravantinos, Gerasimos g   Koutras, Angelos h   Christodoulou, Christos i   Pectasides, Dimitrios j   more..


Author keywords

Anthracyclines; Cish; Early breast cancer; Gene amplification; Her2; Mrna expression; Randomized study; Taxanes; Top2a

Indexed keywords

CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; KI 67 ANTIGEN; MESSENGER RNA; METHOTREXATE; PACLITAXEL; PROTEIN; TOPOISOMERASE II ALPHA; TOPOLLA PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; ESTROGEN RECEPTOR; HER2 PROTEIN, HUMAN; PARAFFIN; PROGESTERONE RECEPTOR; TUMOR ANTIGEN;

EID: 84855568731     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-10     Document Type: Article
Times cited : (47)

References (73)
  • 1
    • 19344364880 scopus 로고    scopus 로고
    • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
    • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717.
    • (2005) Lancet , vol.365 , pp. 1687-1717
  • 2
    • 31344450632 scopus 로고    scopus 로고
    • Medical treatment of early breast cancer. III: chemotherapy
    • Smith I, Chua S. Medical treatment of early breast cancer. III: chemotherapy. BMJ (Clinical research ed 2006, 332:161-162.
    • (2006) BMJ (Clinical research ed , vol.332 , pp. 161-162
    • Smith, I.1    Chua, S.2
  • 3
    • 33644840267 scopus 로고    scopus 로고
    • Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study
    • 10.1200/JCO.2005.02.5841, 16314622
    • Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol 2005, 23:8597-8605. 10.1200/JCO.2005.02.5841, 16314622.
    • (2005) J Clin Oncol , vol.23 , pp. 8597-8605
    • Doyle, J.J.1    Neugut, A.I.2    Jacobson, J.S.3    Grann, V.R.4    Hershman, D.L.5
  • 4
    • 33847758628 scopus 로고    scopus 로고
    • Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy
    • 10.1093/jnci/djk028, 17284714
    • Hershman D, Neugut AI, Jacobson JS, Wang J, Tsai WY, McBride R, Bennett CL, Grann VR. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. Journal of the National Cancer Institute 2007, 99:196-205. 10.1093/jnci/djk028, 17284714.
    • (2007) Journal of the National Cancer Institute , vol.99 , pp. 196-205
    • Hershman, D.1    Neugut, A.I.2    Jacobson, J.S.3    Wang, J.4    Tsai, W.Y.5    McBride, R.6    Bennett, C.L.7    Grann, V.R.8
  • 5
    • 66249091930 scopus 로고    scopus 로고
    • The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine
    • 10.1634/theoncologist.2008-0230, 19346299
    • Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. The oncologist 2009, 14:320-368. 10.1634/theoncologist.2008-0230, 19346299.
    • (2009) The oncologist , vol.14 , pp. 320-368
    • Ross, J.S.1    Slodkowska, E.A.2    Symmans, W.F.3    Pusztai, L.4    Ravdin, P.M.5    Hortobagyi, G.N.6
  • 6
    • 37049183697 scopus 로고
    • Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
    • Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (New York, NY 1987, 235:177-182.
    • (1987) Science (New York, NY , vol.235 , pp. 177-182
    • Slamon, D.J.1    Clark, G.M.2    Wong, S.G.3    Levin, W.J.4    Ullrich, A.5    McGuire, W.L.6
  • 7
    • 33750615735 scopus 로고    scopus 로고
    • Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes--molecular basis for combination chemotherapy in cancer
    • 10.2174/156800906778742497, 17100565
    • Jarvinen TA, Liu ET. Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes--molecular basis for combination chemotherapy in cancer. Current cancer drug targets 2006, 6:579-602. 10.2174/156800906778742497, 17100565.
    • (2006) Current cancer drug targets , vol.6 , pp. 579-602
    • Jarvinen, T.A.1    Liu, E.T.2
  • 9
    • 38049103907 scopus 로고    scopus 로고
    • HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials
    • 10.1093/jnci/djm252, 18159072
    • Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M, Pfeffer U, Bruzzi P. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. Journal of the National Cancer Institute 2008, 100:14-20. 10.1093/jnci/djm252, 18159072.
    • (2008) Journal of the National Cancer Institute , vol.100 , pp. 14-20
    • Gennari, A.1    Sormani, M.P.2    Pronzato, P.3    Puntoni, M.4    Colozza, M.5    Pfeffer, U.6    Bruzzi, P.7
  • 10
    • 17944375163 scopus 로고    scopus 로고
    • HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide
    • 10.1023/A:1011669223035, 11583189
    • Di Leo A, Larsimont D, Gancberg D, Jarvinen T, Beauduin M, Vindevoghel A, Michel J, Focan CH, Ries F, Gobert PH, et al. HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol 2001, 12:1081-1089. 10.1023/A:1011669223035, 11583189.
    • (2001) Ann Oncol , vol.12 , pp. 1081-1089
    • Di Leo, A.1    Larsimont, D.2    Gancberg, D.3    Jarvinen, T.4    Beauduin, M.5    Vindevoghel, A.6    Michel, J.7    Focan, C.H.8    Ries, F.9    Gobert, P.H.10
  • 12
    • 0034923502 scopus 로고    scopus 로고
    • DNA topoisomerases: structure, function, and mechanism
    • 10.1146/annurev.biochem.70.1.369, 11395412
    • Champoux JJ. DNA topoisomerases: structure, function, and mechanism. Annual review of biochemistry 2001, 70:369-413. 10.1146/annurev.biochem.70.1.369, 11395412.
    • (2001) Annual review of biochemistry , vol.70 , pp. 369-413
    • Champoux, J.J.1
  • 14
    • 15544382365 scopus 로고    scopus 로고
    • Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines
    • 10.1016/j.humpath.2004.11.010, 15791569
    • Hicks DG, Tubbs RR. Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. Human pathology 2005, 36:250-261. 10.1016/j.humpath.2004.11.010, 15791569.
    • (2005) Human pathology , vol.36 , pp. 250-261
    • Hicks, D.G.1    Tubbs, R.R.2
  • 15
    • 24044526879 scopus 로고    scopus 로고
    • Isolated tumor cells in the bone marrow (ITC-BM) of breast cancer patients before and after anthracyclin based therapy: influenced by the HER2- and Topoisomerase IIalpha-status of the primary tumor?
    • 10.1007/s00432-005-0683-y, 15887027
    • Schindlbeck C, Janni W, Shabani N, Kornmeier A, Rack B, Rjosk D, Gerber B, Braun S, Sommer H, Friese K. Isolated tumor cells in the bone marrow (ITC-BM) of breast cancer patients before and after anthracyclin based therapy: influenced by the HER2- and Topoisomerase IIalpha-status of the primary tumor?. Journal of cancer research and clinical oncology 2005, 131:539-546. 10.1007/s00432-005-0683-y, 15887027.
    • (2005) Journal of cancer research and clinical oncology , vol.131 , pp. 539-546
    • Schindlbeck, C.1    Janni, W.2    Shabani, N.3    Kornmeier, A.4    Rack, B.5    Rjosk, D.6    Gerber, B.7    Braun, S.8    Sommer, H.9    Friese, K.10
  • 16
    • 34447295638 scopus 로고    scopus 로고
    • Chromogenic and fluorescent in situ hybridization in breast cancer
    • 10.1016/j.humpath.2007.04.011, 17640550
    • Lambros MB, Natrajan R, Reis-Filho JS. Chromogenic and fluorescent in situ hybridization in breast cancer. Human pathology 2007, 38:1105-1122. 10.1016/j.humpath.2007.04.011, 17640550.
    • (2007) Human pathology , vol.38 , pp. 1105-1122
    • Lambros, M.B.1    Natrajan, R.2    Reis-Filho, J.S.3
  • 17
    • 27744538443 scopus 로고    scopus 로고
    • Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group
    • 10.1093/annonc/mdi366, 16148021
    • Fountzilas G, Skarlos D, Dafni U, Gogas H, Briasoulis E, Pectasides D, Papadimitriou C, Markopoulos C, Polychronis A, Kalofonos HP, et al. Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 2005, 16:1762-1771. 10.1093/annonc/mdi366, 16148021.
    • (2005) Ann Oncol , vol.16 , pp. 1762-1771
    • Fountzilas, G.1    Skarlos, D.2    Dafni, U.3    Gogas, H.4    Briasoulis, E.5    Pectasides, D.6    Papadimitriou, C.7    Markopoulos, C.8    Polychronis, A.9    Kalofonos, H.P.10
  • 18
    • 69849093714 scopus 로고    scopus 로고
    • Are HER2 and TOP2A useful as prognostic or predictive biomarkers for anthracycline-based adjuvant chemotherapy for breast cancer?
    • 10.1200/JCO.2009.22.8361, 19620479
    • Pritchard KI. Are HER2 and TOP2A useful as prognostic or predictive biomarkers for anthracycline-based adjuvant chemotherapy for breast cancer?. J Clin Oncol 2009, 27:3875-3876. 10.1200/JCO.2009.22.8361, 19620479.
    • (2009) J Clin Oncol , vol.27 , pp. 3875-3876
    • Pritchard, K.I.1
  • 20
    • 0036178508 scopus 로고    scopus 로고
    • Tissue microarrays: a powerful tool for high-throughput analysis of clinical specimens: a review of the method with validation data
    • 10.1097/00022744-200203000-00001, 11893029
    • Skacel M, Skilton B, Pettay JD, Tubbs RR. Tissue microarrays: a powerful tool for high-throughput analysis of clinical specimens: a review of the method with validation data. Appl Immunohistochem Mol Morphol 2002, 10:1-6. 10.1097/00022744-200203000-00001, 11893029.
    • (2002) Appl Immunohistochem Mol Morphol , vol.10 , pp. 1-6
    • Skacel, M.1    Skilton, B.2    Pettay, J.D.3    Tubbs, R.R.4
  • 21
    • 61349090481 scopus 로고    scopus 로고
    • Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation
    • 10.1159/000207504, 19262067
    • Christodoulou C, Kostopoulos I, Kalofonos HP, Lianos E, Bobos M, Briasoulis E, Gogas H, Razis E, Skarlos DV, Fountzilas G. Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation. Oncology 2009, 76:275-285. 10.1159/000207504, 19262067.
    • (2009) Oncology , vol.76 , pp. 275-285
    • Christodoulou, C.1    Kostopoulos, I.2    Kalofonos, H.P.3    Lianos, E.4    Bobos, M.5    Briasoulis, E.6    Gogas, H.7    Razis, E.8    Skarlos, D.V.9    Fountzilas, G.10
  • 22
    • 0033694650 scopus 로고    scopus 로고
    • Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples
    • 10.1016/S0002-9440(10)64785-2, 1885742, 11073807
    • Tanner M, Gancberg D, Di Leo A, Larsimont D, Rouas G, Piccart MJ, Isola J. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. The American journal of pathology 2000, 157:1467-1472. 10.1016/S0002-9440(10)64785-2, 1885742, 11073807.
    • (2000) The American journal of pathology , vol.157 , pp. 1467-1472
    • Tanner, M.1    Gancberg, D.2    Di Leo, A.3    Larsimont, D.4    Rouas, G.5    Piccart, M.J.6    Isola, J.7
  • 24
    • 69549108768 scopus 로고    scopus 로고
    • RNA extraction from archival formalin-fixed paraffin-embedded tissue: a comparison of manual, semiautomated, and fully automated purification methods
    • 10.1373/clinchem.2008.122572, 19617290
    • Bohmann K, Hennig G, Rogel U, Poremba C, Mueller BM, Fritz P, Stoerkel S, Schaefer KL. RNA extraction from archival formalin-fixed paraffin-embedded tissue: a comparison of manual, semiautomated, and fully automated purification methods. Clin Chem 2009, 55:1719-1727. 10.1373/clinchem.2008.122572, 19617290.
    • (2009) Clin Chem , vol.55 , pp. 1719-1727
    • Bohmann, K.1    Hennig, G.2    Rogel, U.3    Poremba, C.4    Mueller, B.M.5    Fritz, P.6    Stoerkel, S.7    Schaefer, K.L.8
  • 25
    • 78649897310 scopus 로고    scopus 로고
    • Automated extraction of DNA and RNA from a single formalin-fixed paraffin-embedded tissue section for analysis of both single-nucleotide polymorphisms and mRNA expression
    • 10.1373/clinchem.2010.151233, 20947696
    • Hennig G, Gehrmann M, Stropp U, Brauch H, Fritz P, Eichelbaum M, Schwab M, Schroth W. Automated extraction of DNA and RNA from a single formalin-fixed paraffin-embedded tissue section for analysis of both single-nucleotide polymorphisms and mRNA expression. Clinical chemistry 2010, 56:1845-1853. 10.1373/clinchem.2010.151233, 20947696.
    • (2010) Clinical chemistry , vol.56 , pp. 1845-1853
    • Hennig, G.1    Gehrmann, M.2    Stropp, U.3    Brauch, H.4    Fritz, P.5    Eichelbaum, M.6    Schwab, M.7    Schroth, W.8
  • 26
    • 79952167236 scopus 로고    scopus 로고
    • Quantitative determination of estrogen receptor, progesterone receptor, and HER2 mRNA in formalin-fixed paraffin-embedded tissue--a new option for predictive biomarker assessment in breast cancer
    • 10.1097/PDM.0b013e3181e3630c, 21326033
    • Muller BM, Kronenwett R, Hennig G, Euting H, Weber K, Bohmann K, Weichert W, Altmann G, Roth C, Winzer KJ, et al. Quantitative determination of estrogen receptor, progesterone receptor, and HER2 mRNA in formalin-fixed paraffin-embedded tissue--a new option for predictive biomarker assessment in breast cancer. Diagn Mol Pathol 2011, 20:1-10. 10.1097/PDM.0b013e3181e3630c, 21326033.
    • (2011) Diagn Mol Pathol , vol.20 , pp. 1-10
    • Muller, B.M.1    Kronenwett, R.2    Hennig, G.3    Euting, H.4    Weber, K.5    Bohmann, K.6    Weichert, W.7    Altmann, G.8    Roth, C.9    Winzer, K.J.10
  • 27
    • 19644388869 scopus 로고    scopus 로고
    • HER-2/neu and topoisomerase IIa gene amplification and protein expression in invasive breast carcinomas: chromogenic in situ hybridization and immunohistochemical analyses
    • 10.1309/PCFK8YTQPYWD534F, 15899781
    • Bhargava R, Lal P, Chen B. HER-2/neu and topoisomerase IIa gene amplification and protein expression in invasive breast carcinomas: chromogenic in situ hybridization and immunohistochemical analyses. American journal of clinical pathology 2005, 123:889-895. 10.1309/PCFK8YTQPYWD534F, 15899781.
    • (2005) American journal of clinical pathology , vol.123 , pp. 889-895
    • Bhargava, R.1    Lal, P.2    Chen, B.3
  • 29
    • 77954526150 scopus 로고    scopus 로고
    • American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer
    • 10.1200/JCO.2009.25.6529, 2881855, 20404251
    • Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010, 28:2784-2795. 10.1200/JCO.2009.25.6529, 2881855, 20404251.
    • (2010) J Clin Oncol , vol.28 , pp. 2784-2795
    • Hammond, M.E.1    Hayes, D.F.2    Dowsett, M.3    Allred, D.C.4    Hagerty, K.L.5    Badve, S.6    Fitzgibbons, P.L.7    Francis, G.8    Goldstein, N.S.9    Hayes, M.10
  • 32
    • 70449420123 scopus 로고    scopus 로고
    • Use of archived specimens in evaluation of prognostic and predictive biomarkers
    • 10.1093/jnci/djp335, 2782246, 19815849
    • Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. Journal of the National Cancer Institute 2009, 101:1446-1452. 10.1093/jnci/djp335, 2782246, 19815849.
    • (2009) Journal of the National Cancer Institute , vol.101 , pp. 1446-1452
    • Simon, R.M.1    Paik, S.2    Hayes, D.F.3
  • 34
    • 78049437579 scopus 로고    scopus 로고
    • Human epidermal growth factor receptor 2 testing: where are we?
    • 10.1200/JCO.2010.29.5071, 20697080
    • De P, Smith BR, Leyland-Jones B. Human epidermal growth factor receptor 2 testing: where are we?. J Clin Oncol 2010, 28:4289-4292. 10.1200/JCO.2010.29.5071, 20697080.
    • (2010) J Clin Oncol , vol.28 , pp. 4289-4292
    • De, P.1    Smith, B.R.2    Leyland-Jones, B.3
  • 35
    • 71049124846 scopus 로고    scopus 로고
    • Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer
    • 10.1016/j.humpath.2009.07.001, 19762065
    • Shah SS, Ketterling RP, Goetz MP, Ingle JN, Reynolds CA, Perez EA, Chen B. Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer. Human pathology 2010, 41:103-106. 10.1016/j.humpath.2009.07.001, 19762065.
    • (2010) Human pathology , vol.41 , pp. 103-106
    • Shah, S.S.1    Ketterling, R.P.2    Goetz, M.P.3    Ingle, J.N.4    Reynolds, C.A.5    Perez, E.A.6    Chen, B.7
  • 36
    • 77951019861 scopus 로고    scopus 로고
    • ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction
    • 10.1158/1078-0432.CCR-09-2471, 20371687
    • Brase JC, Schmidt M, Fischbach T, Sultmann H, Bojar H, Koelbl H, Hellwig B, Rahnenfuhrer J, Hengstler JG, Gehrmann MC. ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction. Clin Cancer Res 2010, 16:2391-2401. 10.1158/1078-0432.CCR-09-2471, 20371687.
    • (2010) Clin Cancer Res , vol.16 , pp. 2391-2401
    • Brase, J.C.1    Schmidt, M.2    Fischbach, T.3    Sultmann, H.4    Bojar, H.5    Koelbl, H.6    Hellwig, B.7    Rahnenfuhrer, J.8    Hengstler, J.G.9    Gehrmann, M.C.10
  • 37
    • 40449131620 scopus 로고    scopus 로고
    • Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study
    • 10.1186/bcr1776, 2242665, 17922920
    • van de Vijver M, Bilous M, Hanna W, Hofmann M, Kristel P, Penault-Llorca F, Ruschoff J. Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study. Breast Cancer Res 2007, 9:R68. 10.1186/bcr1776, 2242665, 17922920.
    • (2007) Breast Cancer Res , vol.9
    • van de Vijver, M.1    Bilous, M.2    Hanna, W.3    Hofmann, M.4    Kristel, P.5    Penault-Llorca, F.6    Ruschoff, J.7
  • 38
    • 73949150777 scopus 로고    scopus 로고
    • Simultaneous detection of TOP2A and HER2 gene amplification by multiplex ligation-dependent probe amplification in breast cancer
    • 10.1038/modpathol.2009.136, 19767729
    • Moelans CB, de Weger RA, van Blokland MT, van der Wall E, van Diest PJ. Simultaneous detection of TOP2A and HER2 gene amplification by multiplex ligation-dependent probe amplification in breast cancer. Mod Pathol 2010, 23:62-70. 10.1038/modpathol.2009.136, 19767729.
    • (2010) Mod Pathol , vol.23 , pp. 62-70
    • Moelans, C.B.1    de Weger, R.A.2    van Blokland, M.T.3    van der Wall, E.4    van Diest, P.J.5
  • 39
    • 77349118709 scopus 로고    scopus 로고
    • Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601)
    • 10.1016/S1470-2045(10)70006-1, 20079691
    • Bartlett JM, Munro AF, Dunn JA, McConkey C, Jordan S, Twelves CJ, Cameron DA, Thomas J, Campbell FM, Rea DW, et al. Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). The lancet oncology 2010, 11:266-274. 10.1016/S1470-2045(10)70006-1, 20079691.
    • (2010) The lancet oncology , vol.11 , pp. 266-274
    • Bartlett, J.M.1    Munro, A.F.2    Dunn, J.A.3    McConkey, C.4    Jordan, S.5    Twelves, C.J.6    Cameron, D.A.7    Thomas, J.8    Campbell, F.M.9    Rea, D.W.10
  • 40
    • 0043145754 scopus 로고    scopus 로고
    • Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer
    • 10.1002/(SICI)1098-2264(199910)26:2<142::AID-GCC6>3.0.CO;2-B, 22250046
    • Jarvinen TA, Tanner M, Barlund M, Borg A, Isola J. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes, chromosomes & cancer 1999, 26:142-150. 10.1002/(SICI)1098-2264(199910)26:2<142::AID-GCC6>3.0.CO;2-B, 22250046.
    • (1999) Genes, chromosomes & cancer , vol.26 , pp. 142-150
    • Jarvinen, T.A.1    Tanner, M.2    Barlund, M.3    Borg, A.4    Isola, J.5
  • 41
    • 70149118628 scopus 로고    scopus 로고
    • Topoisomerase II alpha gene copy loss has adverse prognostic significance in ERBB2-amplified breast cancer: a retrospective study of paraffin-embedded tumor specimens and medical charts
    • 10.1186/1756-8722-1-12, 3248937, 22210330
    • Usha L, Tabesh B, Morrison LE, Rao RD, Jacobson K, Zhu A, Basu S, Coon JS. Topoisomerase II alpha gene copy loss has adverse prognostic significance in ERBB2-amplified breast cancer: a retrospective study of paraffin-embedded tumor specimens and medical charts. Journal of hematology & oncology 2008, 1:12. 10.1186/1756-8722-1-12, 3248937, 22210330.
    • (2008) Journal of hematology & oncology , vol.1 , pp. 12
    • Usha, L.1    Tabesh, B.2    Morrison, L.E.3    Rao, R.D.4    Jacobson, K.5    Zhu, A.6    Basu, S.7    Coon, J.S.8
  • 42
    • 79952323665 scopus 로고    scopus 로고
    • Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy
    • 10.1200/JCO.2009.27.5644, 21189395
    • Press MF, Sauter G, Buyse M, Bernstein L, Guzman R, Santiago A, Villalobos IE, Eiermann W, Pienkowski T, Martin M, et al. Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol 2011, 29:859-867. 10.1200/JCO.2009.27.5644, 21189395.
    • (2011) J Clin Oncol , vol.29 , pp. 859-867
    • Press, M.F.1    Sauter, G.2    Buyse, M.3    Bernstein, L.4    Guzman, R.5    Santiago, A.6    Villalobos, I.E.7    Eiermann, W.8    Pienkowski, T.9    Martin, M.10
  • 43
    • 0037333625 scopus 로고    scopus 로고
    • Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy
    • 10.1016/S0959-8049(02)00745-1, 12628842
    • Park K, Kim J, Lim S, Han S. Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. Eur J Cancer 2003, 39:631-634. 10.1016/S0959-8049(02)00745-1, 12628842.
    • (2003) Eur J Cancer , vol.39 , pp. 631-634
    • Park, K.1    Kim, J.2    Lim, S.3    Han, S.4
  • 47
    • 69549124028 scopus 로고    scopus 로고
    • Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event
    • 10.1038/modpathol.2009.78, 19448591
    • Yeh IT, Martin MA, Robetorye RS, Bolla AR, McCaskill C, Shah RK, Gorre ME, Mohammed MS, Gunn SR. Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event. Mod Pathol 2009, 22:1169-1175. 10.1038/modpathol.2009.78, 19448591.
    • (2009) Mod Pathol , vol.22 , pp. 1169-1175
    • Yeh, I.T.1    Martin, M.A.2    Robetorye, R.S.3    Bolla, A.R.4    McCaskill, C.5    Shah, R.K.6    Gorre, M.E.7    Mohammed, M.S.8    Gunn, S.R.9
  • 49
    • 0036554731 scopus 로고    scopus 로고
    • Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer
    • Coon JS, Marcus E, Gupta-Burt S, Seelig S, Jacobson K, Chen S, Renta V, Fronda G, Preisler HD. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 2002, 8:1061-1067.
    • (2002) Clin Cancer Res , vol.8 , pp. 1061-1067
    • Coon, J.S.1    Marcus, E.2    Gupta-Burt, S.3    Seelig, S.4    Jacobson, K.5    Chen, S.6    Renta, V.7    Fronda, G.8    Preisler, H.D.9
  • 50
    • 1542343905 scopus 로고    scopus 로고
    • Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples
    • 10.1002/gcc.20008, 22250046
    • Mueller RE, Parkes RK, Andrulis I, O'Malley FP. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. Genes, chromosomes & cancer 2004, 39:288-297. 10.1002/gcc.20008, 22250046.
    • (2004) Genes, chromosomes & cancer , vol.39 , pp. 288-297
    • Mueller, R.E.1    Parkes, R.K.2    Andrulis, I.3    O'Malley, F.P.4
  • 53
    • 0034461638 scopus 로고    scopus 로고
    • Influence of cell cycle and oncogene activity upon topoisomerase IIalpha expression and drug toxicity
    • 10.1128/MCB.20.24.9127-9137.2000, 102171, 11094065
    • Stacey DW, Hitomi M, Chen G. Influence of cell cycle and oncogene activity upon topoisomerase IIalpha expression and drug toxicity. Molecular and cellular biology 2000, 20:9127-9137. 10.1128/MCB.20.24.9127-9137.2000, 102171, 11094065.
    • (2000) Molecular and cellular biology , vol.20 , pp. 9127-9137
    • Stacey, D.W.1    Hitomi, M.2    Chen, G.3
  • 55
    • 65549132064 scopus 로고    scopus 로고
    • HMGB1 and HMGB2 proteins up-regulate cellular expression of human topoisomerase IIalpha
    • 10.1093/nar/gkp067, 2673423, 19223331
    • Stros M, Polanska E, Struncova S, Pospisilova S. HMGB1 and HMGB2 proteins up-regulate cellular expression of human topoisomerase IIalpha. Nucleic acids research 2009, 37:2070-2086. 10.1093/nar/gkp067, 2673423, 19223331.
    • (2009) Nucleic acids research , vol.37 , pp. 2070-2086
    • Stros, M.1    Polanska, E.2    Struncova, S.3    Pospisilova, S.4
  • 57
    • 34249110814 scopus 로고    scopus 로고
    • Measuring proliferation in breast cancer: practicalities and applications
    • 10.1186/bcr1618, 1797032, 17164010
    • Beresford MJ, Wilson GD, Makris A. Measuring proliferation in breast cancer: practicalities and applications. Breast Cancer Res 2006, 8:216. 10.1186/bcr1618, 1797032, 17164010.
    • (2006) Breast Cancer Res , vol.8 , pp. 216
    • Beresford, M.J.1    Wilson, G.D.2    Makris, A.3
  • 58
    • 64649105115 scopus 로고    scopus 로고
    • DNA topoisomerase II and its growing repertoire of biological functions
    • 10.1038/nrc2608, 2730144, 19377505
    • Nitiss JL. DNA topoisomerase II and its growing repertoire of biological functions. Nature reviews 2009, 9:327-337. 10.1038/nrc2608, 2730144, 19377505.
    • (2009) Nature reviews , vol.9 , pp. 327-337
    • Nitiss, J.L.1
  • 59
    • 33750512148 scopus 로고    scopus 로고
    • Predictive value of HER-2 and Topoisomerase IIalpha in response to primary doxorubicin in breast cancer
    • 10.1016/j.ejca.2006.06.013, 16935488
    • Arriola E, Moreno A, Varela M, Serra JM, Falo C, Benito E, Escobedo AP. Predictive value of HER-2 and Topoisomerase IIalpha in response to primary doxorubicin in breast cancer. Eur J Cancer 2006, 42:2954-2960. 10.1016/j.ejca.2006.06.013, 16935488.
    • (2006) Eur J Cancer , vol.42 , pp. 2954-2960
    • Arriola, E.1    Moreno, A.2    Varela, M.3    Serra, J.M.4    Falo, C.5    Benito, E.6    Escobedo, A.P.7
  • 60
    • 75249083420 scopus 로고    scopus 로고
    • Ki67 in breast cancer: prognostic and predictive potential
    • 10.1016/S1470-2045(09)70262-1, 20152769
    • Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. The lancet oncology 2010, 11:174-183. 10.1016/S1470-2045(09)70262-1, 20152769.
    • (2010) The lancet oncology , vol.11 , pp. 174-183
    • Yerushalmi, R.1    Woods, R.2    Ravdin, P.M.3    Hayes, M.M.4    Gelmon, K.A.5
  • 61
    • 58549106588 scopus 로고    scopus 로고
    • Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer
    • 10.1007/s10549-008-9964-x, 18340528
    • Rody A, Karn T, Ruckhaberle E, Muller V, Gehrmann M, Solbach C, Ahr A, Gatje R, Holtrich U, Kaufmann M. Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer. Breast cancer research and treatment 2009, 113:457-466. 10.1007/s10549-008-9964-x, 18340528.
    • (2009) Breast cancer research and treatment , vol.113 , pp. 457-466
    • Rody, A.1    Karn, T.2    Ruckhaberle, E.3    Muller, V.4    Gehrmann, M.5    Solbach, C.6    Ahr, A.7    Gatje, R.8    Holtrich, U.9    Kaufmann, M.10
  • 63
    • 64649090292 scopus 로고    scopus 로고
    • Targeting DNA topoisomerase II in cancer chemotherapy
    • 2748742, 19377506
    • Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nature reviews 2009, 9:338-350. 2748742, 19377506.
    • (2009) Nature reviews , vol.9 , pp. 338-350
    • Nitiss, J.L.1
  • 64
    • 32944475493 scopus 로고    scopus 로고
    • Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group
    • 10.1200/JCO.2005.11.007, 16234514
    • Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV, Schonau A, Gunnarsdottir K, Olsen KE, Mouridsen H, Ejlertsen B. retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 2005, 23:7483-7490. 10.1200/JCO.2005.11.007, 16234514.
    • (2005) J Clin Oncol , vol.23 , pp. 7483-7490
    • Knoop, A.S.1    Knudsen, H.2    Balslev, E.3    Rasmussen, B.B.4    Overgaard, J.5    Nielsen, K.V.6    Schonau, A.7    Gunnarsdottir, K.8    Olsen, K.E.9    Mouridsen, H.10    Ejlertsen, B.11
  • 66
    • 33846585955 scopus 로고    scopus 로고
    • Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response
    • Rody A, Karn T, Gatje R, Ahr A, Solbach C, Kourtis K, Munnes M, Loibl S, Kissler S, Ruckhaberle E, et al. Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response. Breast (Edinburgh, Scotland) 2007, 16:86-93.
    • (2007) Breast (Edinburgh, Scotland) , vol.16 , pp. 86-93
    • Rody, A.1    Karn, T.2    Gatje, R.3    Ahr, A.4    Solbach, C.5    Kourtis, K.6    Munnes, M.7    Loibl, S.8    Kissler, S.9    Ruckhaberle, E.10
  • 67
    • 56749104283 scopus 로고    scopus 로고
    • Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study
    • 10.1038/sj.bjc.6604769, 2600696, 18985033
    • Koutras AK, Kalogeras KT, Dimopoulos MA, Wirtz RM, Dafni U, Briasoulis E, Pectasides D, Gogas H, Christodoulou C, Aravantinos G, et al. Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. British journal of cancer 2008, 99:1775-1785. 10.1038/sj.bjc.6604769, 2600696, 18985033.
    • (2008) British journal of cancer , vol.99 , pp. 1775-1785
    • Koutras, A.K.1    Kalogeras, K.T.2    Dimopoulos, M.A.3    Wirtz, R.M.4    Dafni, U.5    Briasoulis, E.6    Pectasides, D.7    Gogas, H.8    Christodoulou, C.9    Aravantinos, G.10
  • 70
    • 79151470854 scopus 로고    scopus 로고
    • Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765)
    • 10.1007/s10549-010-1316-y, 21190079
    • Noske A, Loibl S, Darb-Esfahani S, Roller M, Kronenwett R, Muller BM, Steffen J, von Toerne C, Wirtz R, Baumann I, et al. Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765). Breast cancer research and treatment 2011, 126:109-117. 10.1007/s10549-010-1316-y, 21190079.
    • (2011) Breast cancer research and treatment , vol.126 , pp. 109-117
    • Noske, A.1    Loibl, S.2    Darb-Esfahani, S.3    Roller, M.4    Kronenwett, R.5    Muller, B.M.6    Steffen, J.7    von Toerne, C.8    Wirtz, R.9    Baumann, I.10
  • 72
    • 42949093222 scopus 로고    scopus 로고
    • Quantitative PCR and HER2 testing in breast cancer: a technical and cost-effectiveness analysis
    • 10.1309/1AKQDQ057PQT9AKX, 18343783
    • Barberis M, Pellegrini C, Cannone M, Arizzi C, Coggi G, Bosari S. Quantitative PCR and HER2 testing in breast cancer: a technical and cost-effectiveness analysis. American journal of clinical pathology 2008, 129:563-570. 10.1309/1AKQDQ057PQT9AKX, 18343783.
    • (2008) American journal of clinical pathology , vol.129 , pp. 563-570
    • Barberis, M.1    Pellegrini, C.2    Cannone, M.3    Arizzi, C.4    Coggi, G.5    Bosari, S.6
  • 73
    • 34249887687 scopus 로고    scopus 로고
    • Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer
    • 10.1373/clinchem.2006.076497, 17463177
    • Cronin M, Sangli C, Liu ML, Pho M, Dutta D, Nguyen A, Jeong J, Wu J, Langone KC, Watson D. Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clinical chemistry 2007, 53:1084-1091. 10.1373/clinchem.2006.076497, 17463177.
    • (2007) Clinical chemistry , vol.53 , pp. 1084-1091
    • Cronin, M.1    Sangli, C.2    Liu, M.L.3    Pho, M.4    Dutta, D.5    Nguyen, A.6    Jeong, J.7    Wu, J.8    Langone, K.C.9    Watson, D.10


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.